

SGLT2 Inhibitors: A New Era in Heart Failure Management

Dr. Shailesh Singh

1Department of Cardiology

Abstract

This editorial examines the transformative impact of SGLT2 inhibitors on heart failure outcomes across the spectrum of ejection fraction.

Introduction

Heart failure remains a leading cause of morbidity and mortality worldwide.

Key Findings

The EMPEROR and DAPA-HF trials demonstrated consistent benefits.

Disclosures

The author has no conflicts of interest to disclose.

Funding

No external funding was received for this work.